MapLight Therapeutics Target Price

Analysts' average 12-month price target for MapLight Therapeutics is $34.

Get informed when a big investor buys or sells

+ Follow

Share Price

$10.46

Average Target Price

$33.88

223.9% upside

16 analysts in the last 4 months

High: $52 | Low: $13

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-31	NeedhamAmi Fadia	$43	311.1% upside
2026-08-14	Canaccord GenuitySumant Kulkarni	$21	100.8% upside
2026-08-14	Raymond James	$31	196.4% upside
2026-08-10	UBS	$13	24.3% upside
2026-07-28	Craig-HallumAdam Vogel	$25	139% upside
2026-07-28	Canaccord GenuitySumant Kulkami	$24	129.4% upside
2026-07-28	Morgan Stanley	$21	100.8% upside
2026-07-28	H.C. WainwrightRaghuram Selvaraju	$26	148.6% upside
2026-07-27	Wolfe ResearchRudy Li	$30	186.8% upside
2026-07-24	Canaccord GenuitySumant Kulkarni	$43	311.1% upside
2026-07-21	UBS	$52	397.1% upside
2026-07-20	BMO Capital	$46	339.8% upside
2026-07-10	Needham	$45	330.2% upside
2026-06-24	Raymond James	$46	339.8% upside
2026-06-23	Craig-Hallum	$40	282.4% upside
2026-06-01	Stifel NicolausPaul Matteis	$36	244.2% upside
2026-05-26	UBSAshwani Verma	$48	358.9% upside
2026-05-21	Craig-HallumAdam Vogel	$43	311.1% upside
2026-05-04	H.C. WainwrightRaghuram Selvaraju	$45	330.2% upside
2025-11-21	Leerink PartnersMarc Goodman	$30	186.8% upside
2025-11-21	JefferiesAndrew Tsai	$32	205.9% upside
2025-11-21	Stifel Nicolaus	$28	167.7% upside
2025-11-21	Morgan Stanley	$34	225% upside

MapLight Therapeutics (MPLT) FAQ

As of the most recent data, MPLT shows a target price of $34. Scroll down for historical charts and peer comparison views.

If MapLight Therapeutics moved to the average analyst target of $34, shares would be roughly 223.9% higher than $10.46. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of MapLight Therapeutics's earnings trajectory.

Besides this target price page, Stockcircle has MapLight Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $34) with ownership activity and broader fundamentals.

MapLight Therapeutics's target price is $34; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.